/PRNewswire/ NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced an agreement with the.
Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers.
Posted on 328
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Byung Ha Lee, Ph.D., as Chief Scientific Officer (CSO) effective March 1
st, 2021. Dr. Lee brings extensive scientific experience to the leadership team, with over 15 years of diverse drug development experience. In this new role, Dr. Lee will lead the effort to further demonstrate the scientific strength and maximize the scientific value of the Company’s products.
“Dr. Lee has been an integral part of our company’s success thus far, and we look forward to his continued scientific leadership as our company moves into the next phase of development and growth,” said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT). “The scientific merit of our lead drug candidate, NT-I7, is much attributed to the strong leadership Dr. Lee has provided to NIT over the p